Intravenous immunoglobulin, pharmacogenomics, and Kawasaki disease

J Microbiol Immunol Infect. 2016 Feb;49(1):1-7. doi: 10.1016/j.jmii.2014.11.001. Epub 2014 Nov 11.

Abstract

Kawasaki disease (KD) is a systemic vasculitis of unknown etiology and it is therefore worth examining the multifactorial interaction of genes and environmental factors. Targeted genetic association and genome-wide association studies have helped to provide a better understanding of KD from infection to the immune-related response. Findings in the past decade have contributed to a major breakthrough in the genetics of KD, with the identification of several genomic regions linked to the pathogenesis of KD, including ITPKC, CD40, BLK, and FCGR2A. This review focuses on the factors associated with the genetic polymorphisms of KD and the pharmacogenomics of the response to treatment in patients with intravenous immunoglobulin resistance.

Keywords: Kawasaki disease; genetic polymorphisms; genome-wide association studies; intravenous immunoglobulin resistance; pharmacogenomics.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Genetic Predisposition to Disease*
  • Genome-Wide Association Study
  • Humans
  • Immunoglobulins, Intravenous / administration & dosage*
  • Immunoglobulins, Intravenous / pharmacokinetics*
  • Mucocutaneous Lymph Node Syndrome / genetics*
  • Mucocutaneous Lymph Node Syndrome / therapy*
  • Pharmacogenetics*

Substances

  • Immunoglobulins, Intravenous